Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations  Melanie Chin, Maya De Zoysa, Robert.

Slides:



Advertisements
Similar presentations
Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient  Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.
Advertisements

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.
P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham 
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
Use of high-dose ibuprofen in a pediatric cystic fibrosis center
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Jodi E. Gustave, Joseph A. Jurcisek, Karen S. McCoy, Steven D
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis  P. Gonçalves.
Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis  Jiangchao Zhao, Charles R. Evans, Lisa A. Carmody,
Katarine Egressy, Michaelene Jansen, Keith C. Meyer 
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
The ease of breathing test tracks clinical changes in cystic fibrosis
Baby bottle steam sterilizers disinfect home nebulizers inoculated with bacterial respiratory pathogens  Dana Towle, Deborah A. Callan, Patricia A. Farrel,
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
Amanda L. Brennan, Khin M. Gyi, David M
The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population  Brandie D. Wagner, Frank J. Accurso,
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients  J.L. Fothergill,
Significance of human β-defensins in the epithelial lining fluid of patients with chronic lower respiratory tract infections  S. Yanagi, J. Ashitani,
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.
A.H. Gifford  Journal of Cystic Fibrosis 
Demographics of glucose metabolism in cystic fibrosis
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw 
E. Saussereau, I. Vachier, R. Chiron, B. Godbert, I. Sermet, N
Physiologic endpoints for clinical studies for cystic fibrosis
Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C
A retrospective analysis of biofilm antibiotic susceptibility testing: A better predictor of clinical response in cystic fibrosis exacerbations  Tara.
Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis  D.W. Reid, R. Latham, I.L.
Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis  Abdul Ashish, Steve.
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas.
Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance  P. Goncalves-Vidigal,
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.
Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic  Amanda L. Griffiths, Danielle F. Wurzel,
Theresa A. Laguna, Cynthia B. Williams, Kyle R
Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire  Joän M. Patterson, Melanie Wall, Jerica.
Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale 
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS  Dorota Sands, Ewa Sapiejka, Grzegorz.
Soluble inflammation markers in nasal lavage from CF patients and healthy controls  Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
CFTR modulators and pregnancy: Our work has only just begun
Beta-lactam allergy in adults with cystic fibrosis
N Dauletbaev, K Viel, R Buhl, T.O.F Wagner, J Bargon 
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa  C.E. Wainwright, A.L. Quittner, D.E.
Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005  Donald R. VanDevanter, Eric P. Elkin,
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population  Elaine.
R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Presentation transcript:

Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations  Melanie Chin, Maya De Zoysa, Robert Slinger, Ena Gaudet, Katherine L. Vandemheen, Francis Chan, Lucie Hyde, Thien-Fah Mah, Wendy Ferris, Ranjeeta Mallick, Shawn D. Aaron  Journal of Cystic Fibrosis  Volume 14, Issue 4, Pages 482-489 (July 2015) DOI: 10.1016/j.jcf.2014.11.009 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Comparison of signs & symptoms of CF pulmonary exacerbations in patients with viral and non-viral exacerbations. Blue columns indicate patients with viral exacerbations, and red columns indicate patients with non-viral exacerbations. * indicates exacerbation criteria where the difference in the two groups was statistically significant. Those patients with virus-triggered exacerbations experienced significantly less dyspnea (p=0.009), and were less likely to have a decreased exercise tolerance (p=0.0195) or new findings on respiratory exam (p=0.0147). Journal of Cystic Fibrosis 2015 14, 482-489DOI: (10.1016/j.jcf.2014.11.009) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Comparison of P. aeruginosa colony counts in sputum during stable, exacerbation, and post-exacerbation assessments. The black circles represent individual sputum samples at exacerbation while mean colony counts at each time point are shown in red circles. Journal of Cystic Fibrosis 2015 14, 482-489DOI: (10.1016/j.jcf.2014.11.009) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Comparison of the change in P. aeruginosa colony counts from stable to exacerbation states, in viral and non-viral exacerbations (reported as log10CFU/ml). Mean change (red bar) for non-viral exacerbations was 0.30log10CFU/ml (95% CI −0.52 to 1.11); mean change for viral exacerbations was −0.29log10CFU/ml (95% CI −0.90 to 0.33). Journal of Cystic Fibrosis 2015 14, 482-489DOI: (10.1016/j.jcf.2014.11.009) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Comparison of the change in P. aeruginosa PCR cycle threshold from stable to exacerbation states, in viral and non-viral exacerbations. Mean change (red bar) for non-viral exacerbations was 0.22cycles (95% CI −1.06 to 1.50); mean change for viral exacerbations was −0.92cycles (95% CI −2.64 to 0.80). Journal of Cystic Fibrosis 2015 14, 482-489DOI: (10.1016/j.jcf.2014.11.009) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions